Polymyositis and Dermatomyositis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

This reports provides a data-driven overview of the current and future competitive landscape in Polymyositis and Dermatomyositis therapeutics.

In 2022, there will be more than 349,000 diagnosed prevalent cases of polymyositis (PM) and 165,000 diagnosed prevalence case of dermatomyositis (DM) across 16 pharmaceutical markets.

There are 13 FDA approved drugs available for the treatment of PM/DM.

The PM and DM pipeline consists of over 21 pharmaceuticals spanning all stages of development, with approximately 50% of drugs in mid to late-stage development.

Commercial sponsors dominate clinical trial development in PM and DM, with the US emerging as the key countries for conducting trials in PM and DM.

Deals involving acquisition of PM/DM assets are the most common types of deals in the US and Europe.

A total of five players are currently developing newer products for the treatment of PM/DM in the late-stage pipeline, suggesting a drastic change in the PM/DM market landscape in the immediate future.

Scope

The publisher's Polymyositis and Dermatomyositis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Polymyositis and Dermatomyositis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Polymyositis and Dermatomyositis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.